We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Bayer confirmed it has completed its previously announced transaction to contribute
the assets of its worldwide plasma products business to Talecris Biotherapeutics,
a newly formed corporation controlled by affiliates of Cerberus Capital Management,
New York, and Ampersand Ventures, Wellesley, Mass.
Vital Images, a provider of enterprise-wide advanced visualization software,
and Toshiba Medical Systems, headquartered in Tochigi, Japan, have agreed to
renew their U.S. and international marketing and distribution agreement for
two years, through 2006.
Milestone Scientific announced that it has entered into binding subscription
agreements for an approximately $3 million private placement of 101,044 units
to institutional accredited investors.
A recent medical convention at the Granvia Hotel in Wakayama, Japan, marked
the commencement of marketing and sales for Current Technology's patented TrichoGenesis
platform in the world's second largest national economy, Japan.
HemoSense announced its filing of a registration statement with the Securities
and Exchange Commission (SEC) for a proposed initial public offering of shares
of its common stock.
OmniCorder Technologies announced that the Centers for Medicare & Medicaid
Services (CMS) has established a new technology Ambulatory Payment Classification
(APC) for the company's BioScanIR System -- a medical imaging modality that provides
a fast, noninvasive, radiation-free method for detecting and managing a wide
variety of diseases that affect blood perfusion -- for U.S. Medicare patients
in an outpatient hospital setting.
Siemens Hearing Instruments has introduced iScan, an in-office ear impression
scanner that allows hearing care professionals to scan ear impressions in their
office and then send the custom product order, including the digital impression,
electronically to the manufacturer for production.
The first patient in the U.S. to be enrolled in the clinical trial called, "Carotid
Angioplasty and Stenting vs. Endarterectomy in Asymptomatic Subjects with Significant
Extracranial Carotid Occlusive Disease Trial," (ACT I) was treated at the
Hoag Heart and Vascular Institute at Hoag Memorial Hospital Presbyterian in
Newport Beach, Calif.